SSG
KPTI icon

Summit Securities Group’s Karyopharm Therapeutics KPTI Stock Holding History

Summit Securities Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2
Closed -$1K – 669
2014
Q3 		$1K Buy
+2
New +$1.13K ﹤0.01% 642

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summit Securities Group's KPTI Position: Q4 2014 in Review

Summit Securities Group sold out of Karyopharm Therapeutics (KPTI) in Q4 2014, closing a stake of 2 shares — an estimated $1K sold.

Summit Securities Group first reported a position in KPTI in Q3 2014 and held it in 1 quarter. The position peaked at $1K in Q3 2014. 81 funds tracked by Wall St. Rank hold KPTI as of Q4 2014.

  • Summit Securities Group reported no remaining Karyopharm Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Summit Securities Group sold 2 Karyopharm Therapeutics shares in Q4 2014, an estimated $1K.
  • Summit Securities Group first reported a position in Karyopharm Therapeutics in Q3 2014 and held it in 1 quarter.
  • Summit Securities Group's Karyopharm Therapeutics position peaked at $1K in Q3 2014.
  • 81 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2014.

Based on Summit Securities Group's 13F filing for Q4 2014, filed 5 Feb 2015.